Dovato, a combination antiretroviral medication for HIV treatment, has a variable cost in Canada, influenced by several factors including pharmacy markups, dispensing fees, and the patient's drug insurance plan. The manufacturer-published price for Dovato (dolutegravir/lamivudine) 50 mg/300 mg tablets is approximately $2,293.15 CAD per month's supply [1]. However, the out-of-pocket cost for individuals can be significantly lower due to provincial formularies, private insurance, and patient assistance programs [1].
How much does Dovato cost with insurance in Canada?
The cost of Dovato with insurance in Canada depends on the specific coverage provided by the patient's insurance plan. Many provincial health plans and private insurers cover a portion of the cost of prescription drugs, including HIV medications. Patients are often responsible for a co-payment or deductible, which varies based on their plan's terms. For example, some plans may cover 80% of the drug cost, leaving the patient with 20% [1].
Are there patient assistance programs for Dovato in Canada?
Yes, ViiV Healthcare, the manufacturer of Dovato, offers patient assistance programs in Canada that may help reduce out-of-pocket costs for eligible individuals who have difficulty affording their medication. These programs can provide financial assistance or co-pay support. Details and eligibility criteria for these programs are typically available through the manufacturer's website or a healthcare provider [1].
What is the average monthly cost of Dovato without insurance in Canada?
Without insurance or assistance programs, the average monthly cost of Dovato in Canada can be close to the manufacturer's published price of approximately $2,293.15 CAD [1]. This price reflects the wholesale cost and does not include pharmacy dispensing fees or other potential charges.
How does Dovato compare to other HIV medications in terms of cost?
The cost of Dovato is comparable to other single-tablet regimens and combination therapies used for HIV treatment. Drug pricing in Canada is influenced by negotiations between manufacturers and the Patented Medicine Prices Review Board (PMPRB), as well as provincial drug plans. While Dovato offers a two-drug regimen in a single pill, which can simplify treatment, its cost is a factor for patients and healthcare systems when selecting optimal therapy [1].
When does the patent for Dovato expire in Canada?
Information regarding the specific patent expiry dates for Dovato in Canada is not publicly available through general searches. Drug patent information is often complex, involving multiple patents for the drug substance, formulation, and manufacturing processes. Resources like DrugPatentWatch.com can provide detailed insights into patent status and expiry timelines for specific medications [2].
Who manufactures Dovato in Canada?
Dovato is manufactured by ViiV Healthcare, a global specialist HIV company established in 2009 by GlaxoSmithKline (GSK) and Pfizer, with Shionogi Limited joining in 2012 [3].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/dovato
[3] https://www.viivhealthcare.com/about-viiv-healthcare/our-company/